Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Merck

Ambrx Snags $2 Billion Takeover, But CEO Dan O'Connor Says Don't Call It 'Hot'

Cancer-focused biotech companies Ambrx and Harpoon snapped up a pair of takeover deals. AMAM stock and HARP stock soared.

Investors Business Daily

Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?

Merck stock is shrugging off seven months of underperformance, shooting more than 7% higher in the first week of 2024.

Investors Business Daily

Merck Hooks Harpoon Therapeutics in 0M Acquisition Spree!

Merck sets sail into new therapeutic waters with the 0 million acquisition of Harpoon Therapeutics, harnessing the power of innovation to navigate treat...

Top News

From analysis to the latest developments in health,
read the most diverse news in one place.

Dow Awaits Key December Jobs Data; Apple Sells Off On Second Downgrade

The Dow Jones was unchanged ahead of December payroll data. Apple got a second downgrade for the week while chip-glut shock drove Mobileye down.

Investors Business Daily

3 Pharma Stock Buys for Last-Minute Year-End Profits

Growing healthcare spending and the use of cutting-edge technologies in the research and development of new drugs have put the pharmaceutical industry in a strong position for growth. With such constructive trends in mind, it's wise to buy fundamentally strong pharma stocks, Merck (MRK), Collegium (COLL) and Johnson & Johnson…

StockNews.com

Looking back on the challenges CEOs faced in 2023, from war to climate change to the A.I. boom

Looking ahead, 2024 likely will be filled with volatility, uncertainty, complexity, and ambiguity. That’s "VUCA" for you.

Fortune

Are These 3 Pharma Stocks Smart Buys for Bullish Investors?

The pharmaceutical industry's outlook looks promising, given robust healthcare spending worldwide and the rapid adoption of advanced digital technologies. Amid this, let’s find out if pharma stocks AbbVie (ABBV), Collegium Pharmaceutical (COLL), and Merck (MRK) are ideal buys now. Read on to know more….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Stock Market Rally Surges To 2023 Highs As Fed Pivots Toward Rate Cuts: Weekly Review

The Dow Jones hit a record high while the S&P 500, Nasdaq and Russell 2000 set 2023 highs as the Fed signaled multiple rate cuts next year.

Investors Business Daily

Stock Market Erases Gains As Indexes Stumble; Solar Stocks Shine

The Dow Jones index reached another high but the market weakened in afternoon trading. CAT stock jumped.

Investors Business Daily

Moderna surges on positive skin-cancer-vaccine trial data

The biotech's stock climbs after it reported progress with a skin-cancer vaccine.

The Street

Moderna Stock Soars On 'Transformational' Potential Of Its Merck-Tied Cancer Vaccine

Moderna's Merck-partnered cancer vaccine reduced the risk of relapse or death by 49% in melanoma patients. Moderna stock soared.

Investors Business Daily

Dow Jones Soars As Fed Chair Powell Gives This Good News; Tesla Rallies As Netflix Nears Entry

The Dow Jones rallied as Fed Chair Powell and the FOMC served up good news. Tesla stock rose despite a recall while Netflix is near an entry.

Investors Business Daily

7 Companies Will Propel Profit More Than 100% Next Year: Analysts

It's only November — but if you're like most investors — 2024 is what matters now. And some S&P 500 companies already look primed to put up big numbers.

Investors Business Daily

Analyzing Pharma Stock Giants: JNJ, MRK, and ABBV

The pharmaceutical industry is set for long-term growth due to growing demand for quality drugs and therapies, an aging population, and the rise in lifestyle-related diseases. Now, let's explore the investment potential of industry giants Merck & Co (MRK), Johnson & Johnson (JNJ), and AbbVie (ABBV). Keep reading.

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

Former Merck CEO Ken Frazier on the responsibility of CEOs to uphold principles despite politics

Plus: Frazier talks about the shareholders who trusted his vision enough to support him in his early days at the helm.

Barchart

The 3 Best Dow Jones Stocks to Invest in Now, According to Wall Street

Analysts are bullish on these three dividend-paying Dow stocks, with consensus "Strong Buy" ratings and more upside expected for this diverse set of blue chips.

Fortune

Ex-Merck CEO Ken Frazier says CEOs must uphold American values

Frazier was one of the first CEOs to publicly distance himself from President Donald Trump.

The Independent UK

COVID-19 treatments to enter the market with a hefty price tag

The COVID-19 treatments millions of have taken for free from the federal government will enter the private market next week with a hefty price tag

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Here's How Merck's Heavyweight Cancer Drug Helped Deliver Another Beat-And-Raise Quarter

Merck's Keytruda continued to pull its weight in the third quarter, helping deliver a beat and raise that could stoked Merck shares.

Investors Business Daily

Roche Follows Merck, Sanofi Into A Red-Hot Immunology Space With A $7.1 Billion Buyout

Roche said Monday it would buy an experimental immunology drug from Roivant and Pfizer for $7.1 billion. But ROIV stock sank.

Investors Business Daily

How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks

Almost 68% of patients responded to an experimental bladder cancer treatment from Merck and Seagen. Merck stock jumped Monday.

Investors Business Daily

Dow Jones Slumps 287 Points, Weighed Down By American Express; Tesla Violates Key Level

The Dow Jones fell sharply with the other major stock indexes ahead of a busy week of high-profile earnings reports in the tech sector.

Barchart

3 Beaten-Down Dow Stocks to Buy in October

Dow Jones industrials, such as Nike, have pulled back significantly amid recent market turmoil, and now trade at a steep discount to consensus price target estimates.

Investors Business Daily

Teva Leans Into Sanofi's 'Pipeline-In-A-Product' Expertise In $1.5 Billion Deal

Teva stock tumbled Wednesday after the company announced it would partner with Sanofi to develop an inflammatory bowel disease treatment.

WEKU

All in: Drugmakers say yes, they'll negotiate with Medicare on price, so reluctantly

Despite at least nine lawsuits against the government, all companies whose drugs are up for Medicare price negotiation will come to the bargaining table.

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.